放射肿瘤学医疗不当行为分析:来自国家比较基准系统十年结果
该研究从美国比较基准系统(CBS)提取2005至2014年102例以放射肿瘤学为主要服务的已结案医疗不当诉讼,分析赔偿支付关联因素。涉及良性疾病、治疗部位错误或剂量错误的案件与赔偿支付相关,头颈及中枢神经系统肿瘤病例占比高且赔偿金额大。
要点
- 放射肿瘤学相关已结案诉讼占CBS全部案件的0.2%,赔偿支付占0.1%。
- 涉及良性疾病(P=.009)、错误部位(P=.001)或错误剂量(P<.001)的案件与赔偿支付相关。
- 头颈和中枢神经系统肿瘤分别占案件的23.9%和10.9%,赔偿支付的41.3%和31.4%。
核心结论
- 涉及放射肿瘤学的已结案医疗不当诉讼虽属罕见事件,但某些人群在已结案索赔中可能被过度代表。
- 这些数据可帮助告知提供者和系统,以最终改善患者安全。
研究设计与样本
- 回顾性分析美国Controlled Risk Insurance Company Strategies比较基准系统(CBS)中2005至2014年已结案的放射肿瘤学案件。
- CBS覆盖约30%的美国已结案医疗不当案件,包括30余家学术医院的经验。
- 由执业放射肿瘤学家提取病例并按患者指控类别、临床损伤严重度、诊疗场所与学术隶属、疾病部位与自然病史、治疗模式及贡献因素分组。
- 在各分类内使用χ2检验变量与赔偿支付的关联。
主要发现
- 放射肿瘤学为主要服务的已结案案件共102例(占CBS全部案件的0.2%),赔偿支付总额13,323,578美元(占CBS全部赔偿支付的0.1%)。
- 赔偿支付中位数为100,000美元。
- 头颈和中枢神经系统肿瘤分别占全部放射肿瘤学案件的23.9%和10.9%,分别占全部赔偿支付的41.3%和31.4%。
- 良性疾病和近距离治疗分别涉及12.0%和15.2%的案件。
- 涉及良性疾病(P=.009)、治疗错误部位(P=.001)或使用错误剂量治疗(P<.001)的案件均与赔偿支付相关。
关键数值与推荐
- 良性疾病案件与赔偿支付相关(P=.009)。
- 治疗错误部位案件与赔偿支付相关(P=.001)。
- 使用错误剂量治疗案件与赔偿支付相关(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medical errors in radiation oncology (RO) practice have received significant national attention over the last decade. Medical errors can lead to malpractice cases. Better characterizing these events can educate providers with the goal of improving patient care. METHODS AND MATERIALS: The Controlled Risk Insurance Company Strategies' Comparative Benchmarking System (CBS) represents approximately 30% of all closed US malpractice cases and includes the experience of more than 30 academic hospitals. Registered nurses trained as clinical taxonomy specialists code each case, and individual case-level details are available. Practicing radiation oncologists extracted all closed RO cases from years 2005 to 2014 and subgrouped them by patient allegation category, clinical injury severity, care setting and academic affiliation, disease site and natural history, treatment modality, and contributing factor. Within categories, χ2 tests were used to test for the variables' association with an indemnity payment. RESULTS: RO was the primary service in 102 closed cases (0.2% of all cases in the CBS), accounting for $13,323,578 in indemnity payments (0.1% of all payments in the CBS). The median indemnity payment was $100,000. Head-and-neck and central nervous system tumors accounted for 23.9% and 10.9% of all RO cases, respectively, and 41.3% and 31.4% of all indemnity payments, respectively. Benign diseases and brachytherapy were involved in 12.0% and 15.2% of cases, respectively. Cases involving benign disease (P = .009), treatment of the wrong site (P = .001), or treatment using the wrong dose (P < .001) were all associated with indemnity payments. The top 5 most expensive cases accounted for nearly 80% of all indemnity payments, and all involved head-and-neck, central nervous system, benign, or brachytherapy cases. CONCLUSIONS: We found that although closed malpractice cases involving RO are rare events, certain populations may be overrepresented in closed claims. These data can help inform providers and systems with the goal of ultimately improving patient safety.
引用
- Royce TJ, Dwyer K, Yu-Moe CW, et al. Medical Malpractice Analysis in Radiation Oncology: A Decade of Results From a National Comparative Benchmarking System. Int J Radiat Oncol Biol Phys. 2018. PMID: 30439486. doi:10.1016/j.ijrobp.2018.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。